

Alzecure - Well-Diversified Neurology Play

Redeye revisits its view of Alzecure in the wake of the company's pipeline progress and recent rights issue. We continue to see an interesting neurology platform case with an exiting year ahead. We argue that the company's current valuation is undemanding and see a solid entry point at these levels.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Alzecure - Well-Diversified Neurology Play